SHANGHAI FUDAN H YC-,10 (F:FDY) — Market Cap & Net Worth
Market Cap & Net Worth: SHANGHAI FUDAN H YC-,10 (FDY)
SHANGHAI FUDAN H YC-,10 (F:FDY) has a market capitalization of $120.04 Million (€102.68 Million) as of May 5, 2026. Listed on the F stock exchange, this Germany-based company holds position #18486 globally and #1715 in its home market, demonstrating a 3.42% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying SHANGHAI FUDAN H YC-,10's stock price €0.30 by its total outstanding shares 340000000 (340.00 Million). Analyse FDY cash generation efficiency to see how efficiently the company converts income to cash.
SHANGHAI FUDAN H YC-,10 Market Cap History: 2020 to 2026
SHANGHAI FUDAN H YC-,10's market capitalization history from 2020 to 2026. Data shows growth from $43.80 Million to $120.04 Million (19.91% CAGR).
SHANGHAI FUDAN H YC-,10 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how SHANGHAI FUDAN H YC-,10's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.17x
SHANGHAI FUDAN H YC-,10's market cap is 0.17 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.96x
SHANGHAI FUDAN H YC-,10's market cap is 2.96 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $55.37 Million | $1.14 Billion | $213.30 Million | 0.05x | 0.26x |
| 2022 | $68.89 Million | $1.03 Billion | $138.00 Million | 0.07x | 0.50x |
| 2023 | $63.16 Million | $850.73 Million | $108.63 Million | 0.07x | 0.58x |
| 2024 | $117.66 Million | $709.40 Million | $39.73 Million | 0.17x | 2.96x |
Competitor Companies of FDY by Market Capitalization
Companies near SHANGHAI FUDAN H YC-,10 in the global market cap rankings as of May 5, 2026.
Key companies related to SHANGHAI FUDAN H YC-,10 by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.15 |
SHANGHAI FUDAN H YC-,10 Historical Marketcap From 2020 to 2026
Between 2020 and today, SHANGHAI FUDAN H YC-,10's market cap moved from $43.80 Million to $ 120.04 Million, with a yearly change of 19.91%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €120.04 Million | -2.58% |
| 2025 | €123.22 Million | +4.73% |
| 2024 | €117.66 Million | +86.28% |
| 2023 | €63.16 Million | -8.31% |
| 2022 | €68.89 Million | +24.41% |
| 2021 | €55.37 Million | +26.41% |
| 2020 | €43.80 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of SHANGHAI FUDAN H YC-,10 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $120.04 Million USD |
| MoneyControl | $120.04 Million USD |
| MarketWatch | $120.04 Million USD |
| marketcap.company | $120.04 Million USD |
| Reuters | $120.04 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About SHANGHAI FUDAN H YC-,10
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., engages in the research, development, manufacture, and sale of bio-pharmaceutical products in the People's Republic of China. It offers genetic engineering platform drugs, including Trop2-SN38 ADC that is in Phase III clinical trials for Triple-negative breast cancer; CD30-DM1 antibody-drug conjugate (ADC), which have complected Phase I clini… Read more